82
lseidman@matcmadison. edu QUALITY: THE BIG (BUT RELATIVELY BRIEF) PICTURE

[email protected] QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

Embed Size (px)

Citation preview

Page 1: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

QUALITY: THE BIG (BUT RELATIVELY BRIEF) PICTURE

Page 2: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

OVERVIEW

Talk about product quality systems In broad way Apply ideas to the various

work places we talked about

Page 3: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

QUALITY SYSTEMS

Broad systems of regulations, standards, or policies that ensure the quality of the final product

Page 4: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

Discussion of product quality and quality systems leads to… Regulatory affairs Interaction of government with

the industry

Which for biotechnology…. Takes us to GMP

Page 5: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

WHAT IS PRODUCT QUALITY?

What is a “good” product in biotechnology?

That depends… Consider biotech:

Research labs Testing labs Production facilities

Page 6: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

QUALITY PRODUCT: RESEARCH LAB

Research lab, knowledge is product: Knowledge of nature

(basic research) Understanding of

technology (applied research, R&D)

Page 7: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

QUALITY SYSTEMS IN RESEARCH LABS

Quality system in research

Ensure meaningful data has been around a long

time It is called:

Page 8: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

“DOING GOOD SCIENCE”

Less formalized than other quality systems

No one book spells it out No laws to obey But it exists

Page 9: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

INFORMAL SYSTEM

Consequences of poor quality product not life-threatening so Government seldom

involved in monitoring research quality

Oversight not generally by outside inspectors or auditors

Page 10: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

BUT THERE IS OVERSIGHT

Oversight is by peersGrant reviewPublicationsReputation

Page 11: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

CHANGE: RESEARCH LABS

Change is good Basis for advances Flexibility is valued Willingness to change

directions is necessary

Page 12: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

SUMMARY: RESEARCH LABS

Quality system: “Doing Good Science”

Least formal Not found in any one book No laws to follow No enforcement by regulatory

agency Change is accepted Oversight is by peers

Page 13: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

Compare and contrast situation in research labs and other work places

Page 14: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

PRODUCT QUALITY: TESTING LAB

Testing lab: Information about samples

that can be relied on when making decisions

Page 15: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

CONSEQUENCES

A poor quality product can be life-threatening or have serious effects

Page 16: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

QUALITY SYSTEMS IN TESTING LABS

Include most of what we call “doing good science” plus

Specific formal requirements Personnel Equipment Training Facilities Documentation…

Page 17: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

You can find a book that spells it out for: Clinical labs Forensic labs Environmental labs…

Page 18: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

ENFORCEMENT: TESTING LABS

Since consequences of poor product can be life-threatening Is outside oversight

FBI EPA Etc.

Page 19: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

CHANGE: TESTING LABS

Change is controlled May improve test methods,

but Test new methods against

old ones Document changes Control change

Page 20: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

PRODUCT QUALITY: PRODUCTION FACILITY

Make tangible items Quality means fulfill

intended purpose Ex.: reagent grade salt

vs road salt vs table salt

Page 21: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

QUALITY SYSTEMS IN PRODUCTION FACILITIES Depends on nature of

product Poor product may or may

not have life-threatening consequences

Page 22: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

SO, FOR EXAMPLE

Products for research use, not generally regulated

Agricultural products are regulated in one way

Pharmaceutical products are regulated in another

Page 23: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

VOLUNTARY STANDARDS

Companies that are not regulated may choose to comply with a product quality system for business reasons

Page 24: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

ISO 9000

ISO 9000 Formal product quality

system Extensive Exists in a series of books Companies comply

voluntarily to improve the quality of products

…and to make more money

Page 25: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

Developed by the International Organization for Standardization (ISO)

International

Page 26: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

OVERSIGHT: ISO 9000

Oversight by outside auditors, paid by company

Page 27: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

CHANGE: ISO 9000

Change is controlled Deviations monitored Operation of systems

maintained in narrow range

Page 28: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

BIOTECH AND MEDICAL PRODUCTS

Many biotech companies that make money make medical/pharmaceutical products

Consequences of poor product can be life-threatening

Page 29: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

SO…

These products are highly regulated by the government

But, it wasn’t always this way…

Page 30: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE
Page 31: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

Gallery Guide Introduction

From http://www.fda.gov/cder/about/history/Gallery/Gallerypg.htm

Page 32: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

http://www.fda.gov/cder/about/history/Gallery/Gallerypg.htm

Page 33: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

http://www.fda.gov/cder/about/history/Gallery/Gallerypg.htm

Page 34: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

http://www.fda.gov/cder/about/history/Page6.htm

Page 35: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

http://www.fda.gov/oc/history/historyoffda/section4.html

Early biomedical device

Page 36: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

“THE JUNGLE”

Upton Sinclair described shocking conditions in food industry in U.S.

Page 37: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

FEDERAL FOOD, DRUG AND COSMETIC ACT 501[351]

Page 38: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

CANNOT SELL ADULTERATED PRODUCTS“A drug or device shall be deemed

adulterated – (a)1 if it consists in whole or part of any filthy…substance (2) (A) If it has been prepared, packed, or held under insanitary conditions whereby it may have been contaminated with filth…

Page 39: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

Or (B) if it is a drug and the methods used in, or the facilities or controls used for, its manufacture, processing, packing, or holding do not conform to or are not operated in conformity with current good manufacturing practice to assure that such drug meets the requirements of the Act as to safety and has the identity and

Page 40: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

strength, and meets the quality and purity characteristics, which it purports or is represented to possess…”

Page 41: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

KEY IDEAS: 1906 FDCA

Adulteration Good manufacturing practices,

which we now call cGMP FDA (Food and Drug

Administration) eventually established to interpret and enforce this law

Page 42: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

SULFANILAMIDE -- 1937

Diethylene glycol used to dissolve sulfanilamide

Hundreds of people died, mainly children

Page 43: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

First drug recall, because the drug was labeled “elixir” and had no alcohol

Page 44: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

KEY IDEAS: 1938 FDCA

Required new drugs to be shown SAFE

Eliminated requirement to prove intent to defraud in drug misbranding cases.

Extended control to cosmetics and therapeutic devices.

Authorized factory inspections…      

Page 45: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

CROSS-CONTAMINATIONSULFATHIAZOLE Nearly 300 deaths and injuries

resulted from sulfathiazole tablets tainted with phenobarbital.

FDA dramatically revised manufacturing and quality controls -- good manufacturing practices (GMPs).

Page 46: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

KEY IDEAS: GMP REGULATIONS 1941

Cover actual manufacturing Raw materials must be good Must have lab testing of raw

materials, samples as you go along, products

Facilities, personnel, equipment must be good

Documentation

Page 47: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

Safety Testing Approval Process

Revised GMP Regulations

1941

Page 48: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

THALIDOMIDE -- 1960

Sedative that appeared safe but in reality caused severe birth defects

Thousands of children affected throughout Europe

Led to tightened laws

Page 49: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

CONTAMINATED IV BAGS --1976

Septicemia 1960s and 1970s there were

many cases caused by IV fluids contaminated with bacteria.

Many people died

Page 50: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

FDA INSPECTIONS

Found serious problems: Contaminated cooling

water Sterilization equipment

that did not reach sterilizing temperature

Contamination

Page 51: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

Pharmaceutical companies had testing programs to monitor final products but Missed contaminated

products

Page 52: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

LED TO:

FDA emphatically states: “Quality, safety and

effectiveness are designed into a product. The quality of a product does not result from inspecting the product; that is, quality cannot be inspected or tested into the finished product.”

Page 53: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

HOW IS QUALITY BUILT INTO A PRODUCT? No single answer Requires:

Skilled personnel Well-designed and maintained

facility Well-constructed processes Proper raw materials Documentation Change control

Page 54: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

VALIDATION

Prove that it all works Test systems under all

possible conditions See how everything works Called “validation”

Page 55: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

ANIMAL TESTING --1976

Major deficiencies in animal testing labs company closed directors jailed

Led to GLP, Good Laboratory Practices

Pre-clinical testing

Page 56: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

SKIP TO PRESENT

Process for regulating drugs and other medical products

May 6, 2003

jANUARY 2011

Page 57: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

LIFE CYCLE OF A DRUG TODAY

Discovery Pharmaceutical company, R&D

department Academic research lab Not usually regulated or inspected

Page 58: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

Early research and development Characterization of product Development of assays Mode of action Chemistry Production method Purification methods

Page 59: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

SAFETY TESTING

Animal testing – follow GLP regulations

Page 60: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

If it is promising, submit Investigational New Drug Application, IND

If approved...

Page 61: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

CLINICAL TESTING

Clinical testing Phase I Safety Phase II Dose Phase III Effectiveness

Follow Good Clinical Practices Regulations

If approved, then…

Page 62: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

MANUFACTURING

Follow extremely strict regulations, GMP

Keep watching for problems

Page 63: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

PRODUCTION FACILITY: CLEAN ROOM

Page 64: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

REGULATIONS

Have, GLP, GCP, GMP (cGMP) Administrative concerns;

principles e.g.personnel, equipment, materials

handling, documentation common to many different

companies and products scientific details limited

Page 65: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

EXAMPLE OF GOOD DESIGN: FACILITY AND HOW PEOPLE WORK

Page 66: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

EXAMPLE: AVOIDING CONTAMINATION IN PCR FACILITY People move in one direction

through PCR facility to avoid contaminating samples with already amplified DNA

People change labcoats before entering PCR facility

Facility is designed to move samples in one direction

Security system

Page 67: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

ENFORCEMENT

Compliance is enforced by government FDA

Page 68: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

CHANGE

Change and variability are disastrous

Product quality hinges on avoiding change, reducing variability

Systems are in place to monitor and track variability

Page 69: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

BIOTECHNOLOGY PRODUCTS

Recombinant DNA techniques used for production of protein therapeutics 1982, recombinant insulin approved

for sale 1986 first monoclonal antibody

product 1987 first product using mammalian

cell line as host

Page 70: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

REGULATORY QUANDRY

Should these products be regulated in an entirely separate way?

From Time Magazine

http://bancroft.berkeley.edu/Exhibits/Biotech/25.html

Page 71: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

Basic answer is that same principles apply

But the details are different – what makes product safe, how do you know, etc.

Page 72: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

REST OF THIS COURSE

We will learn basic lab techniques

From a quality perspective Metrology

What makes a good measurement

Solutions How do we know our solutions

are right?

Page 73: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

CONSIDER ANTHRAX VACCINE

Political story Vaccine has been accused of

causing Gulf War Syndrome Recent cases of illness Manufacture of vaccine,

Bioport

Page 74: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

ONE PAGE OF 483

From 1998, 19 pages long First line is key:

“The manufacturing process for Anthrax Vaccine is not validated.”

Page 75: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

1a and 1b

Critical, key parameters in the fermentation process that produces the protective antigen that constitutes part of the vaccine should have been established:

Page 76: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

Age of bacterial strain Conditions in the fermenter Formulation of the bacterial nutrient

broth Operating parameters such as the

temperature, pressure, time, pH, stir times, agitation rates, vessel atmosphere, etc.

Page 77: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

Sampling periodically during antigen isolation and analyses whose results could illustrate acceptable progress

Page 78: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

Assessing ability of tank to heat and cool its contents consistently and uniformly

Testing the agitator for producing a homogenous suspension

Testing the materials used to make the tank to be sure they don’t adversely affect contents

Testing tank fittings, etc.

Page 79: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

1f

Effect of hold times was not evaluated Violates 21CFR211.111 “Time

limitations on production” which states that “time limits for the completion of each phase of production shall be established to assure the quality of the final product”.

Page 80: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

1d

The efficacy of a particular sporocide needs to be proven in the firm’s facility Conduct environmental monitoring

and identify the organisms recovered

See if these strains are destroyed by the sporocide; record effectiveness

Page 81: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

These parameters should have been clearly tested, monitored, and documented during a prevalidation study to demonstrate what quality of product is produced under specific processing conditions.

Page 82: Lseidman@matcmadison.edu QUALITY: THE BIG ( BUT RELATIVELY BRIEF ) PICTURE

lseidman@matcmadison.

edu

WHAT CAN BE READ INTO THE 483S?

“The firm’s processing, testing, and monitoring was effectively a “black box”. Ingredients in – vaccine out! Someone understood the “tricks of the trade” but, for some reason, there was no documented evidence that a consistent manufacturing process or control system was in place!”.